Discovery of a Potent and Orally Bioavailable Zwitterionic Series of Selective Estrogen Receptor Degrader-Antagonists
Journal of Medicinal Chemistry · 2023
DOI: 10.1021/acs.jmedchem.2c01964 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von James S Scott und 42 weiteren Autor:innen. Beteiligte Einrichtung: Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom. Hauptthemen laut MEDLINE: Receptors, Estrogen, Breast Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
Herein, we report the optimization of a meta-substituted series of selective estrogen receptor degrader (SERD) antagonists for the treatment of ER+ breast cancer. Structure-based design together with the use of modeling and NMR to favor the bioactive conformation led to a highly potent series of basic SERDs with promising physicochemical properties. Issues with hERG activity resulted in a strategy of zwitterion formation and ultimately in the identification of 38. This compound was shown to be a highly potent SERD capable of effectively degrading ERα in both MCF-7 and CAMA-1 cell lines. The low lipophilicity and zwitterionic nature led to a SERD with a clean secondary pharmacology profile and no hERG activity. Favorable physicochemical properties resulted in good oral bioavailability in preclinical species and potent in vivo activity in a mouse xenograft model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
- Discovery Sciences R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
- Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.
- Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB2 OAA, United Kingdom.
- Advanced Drug Delivery, Pharmaceutical Sciences, R&D, Boston, Massachusetts 02451, United States.
ORCID-Profile: James S Scott, Bernard Barlaam, Rodrigo J Carbajo, Carrie J B Larner, J Willem M Nissink, Daniel H O'Donovan, Bin Yang
Zitieren
APA
Scott, J. S., Stead, D., Barlaam, B., Breed, J., Carbajo, R. J., Chiarparin, E., Cureton, N., Davey, P. R. J., Fisher, D. I., Gangl, E. T., Grebe, T., Greenwood, R. D., Hande, S., Hatoum-Mokdad, H., Hughes, S. J., Hunt, T. A., Johnson, T., Kavanagh, S. L., Klinowska, T. C. M., …, & Yang, W. (2023). Discovery of a Potent and Orally Bioavailable Zwitterionic Series of Selective Estrogen Receptor Degrader-Antagonists. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.2c01964
Vancouver
Scott JS, Stead D, Barlaam B, Breed J, Carbajo RJ, Chiarparin E, et al. Discovery of a Potent and Orally Bioavailable Zwitterionic Series of Selective Estrogen Receptor Degrader-Antagonists. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.2c01964
BibTeX
@article{Scott2023,
author = {Scott, James S and Stead, Darren and Barlaam, Bernard and Breed, Jason and Carbajo, Rodrigo J and Chiarparin, Elisabetta and Cureton, Natalie and Davey, Paul R J and Fisher, David I and Gangl, Eric T and Grebe, Tyler and Greenwood, Ryan D and Hande, Sudhir and Hatoum-Mokdad, Holia and Hughes, Samantha J and Hunt, Thomas A and Johnson, Tony and Kavanagh, Stefan L and Klinowska, Teresa C M and Larner, Carrie J B and Lawson, Mandy and Lister, Andrew S and Longmire, David and Marden, Stacey and McGuire, Thomas M and McMillan, Caroline and McMurray, Lindsay and Morrow, Christopher J and Nissink, J Willem M and Moss, Thomas A and O'Donovan, Daniel H and Polanski, Radoslaw and Stokes, Stephen and Thakur, Kumar and Trueman, Dawn and Truman, Caroline and Tucker, Michael J and Wang, Haixia and Whalley, Nicky and Wu, Dedong and Wu, Ye and Yang, Bin and Yang, Wenzhan},
title = {Discovery of a Potent and Orally Bioavailable Zwitterionic Series of Selective Estrogen Receptor Degrader-Antagonists},
journal = {Journal of Medicinal Chemistry},
year = {2023},
doi = {10.1021/acs.jmedchem.2c01964}
}
EUVIMED